Serum Institute of India Set to Acquire Stake in IntegriMedical

The Serum Institute of India (SII) planning to strategically invest in IntegriMedical by acquiring a 20% stake, aiming to advance the development of needle-free injection system (N-FIS) technology. The investment aligns with SII’s goal to enhance patient compliance, reduce needle-stick injuries, and improve the effectiveness of liquid medications.

N-FIS technology uses a mechanically powered high-velocity jet stream to deliver drugs and biologics. Designed to provide a pain-free experience, the system is particularly beneficial for patients with needle phobia, making medication administration more comfortable and stress-free.

As reported by Pharmaceutical Technology, N-FIS has obtained regulatory approvals in India, Europe, and the US. Additionally, it holds International Organisation for Standardisation 13485 certification and a US patent.

Also Read |  Health Ministry approves a more effective and shorter treatment regimen for drug-resistant TB in India